AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Telix Pharmaceuticals Limited American Depositary Shares
XNAS · usd
SIC 5122 · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
FIGI BBG01N69K9Y3
9.15▼ 0.39 (-4.09%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
9.54
Day's Range
9.11 – 9.30
52-Week Range
6.28 – 13.11
Volume
413.4K
Avg Volume
468.0K
Share Statistics
Shares Outstanding
Employees
1,184
Exchange
XNAS
Listed
2024-11-13
Share count as of December 31, 2025

Telix Pharmaceuticals Limited American Depositary Shares (TLX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Telix Pharmaceuticals Limited American Depositary Shares (TLX)
What is Telix Pharmaceuticals Limited American Depositary Shares's Market Cap?
Telix Pharmaceuticals Limited American Depositary Shares's Market Cap is $3.1B, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's Enterprise Value?
Telix Pharmaceuticals Limited American Depositary Shares's Enterprise Value is $3.4B, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's Trailing P/E?
Telix Pharmaceuticals Limited American Depositary Shares's Trailing P/E is 92.5×, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's Price / Sales?
Telix Pharmaceuticals Limited American Depositary Shares's Price / Sales is 3.5×, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's EV / Revenue?
Telix Pharmaceuticals Limited American Depositary Shares's EV / Revenue is 3.8×, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's EV / EBITDA?
Telix Pharmaceuticals Limited American Depositary Shares's EV / EBITDA is 39.5×, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's Revenue (TTM)?
Telix Pharmaceuticals Limited American Depositary Shares's Revenue (TTM) is $890.8M, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's Net Income (TTM)?
Telix Pharmaceuticals Limited American Depositary Shares's Net Income (TTM) is $33.5M, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's EBITDA?
Telix Pharmaceuticals Limited American Depositary Shares's EBITDA is $88.8M, based on as-reported figures from SEC (XBRL) filings.
What is Telix Pharmaceuticals Limited American Depositary Shares's Diluted EPS (TTM)?
Telix Pharmaceuticals Limited American Depositary Shares's Diluted EPS (TTM) is 0.10, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TLXAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Continuing operations
Revenue from contracts with customers
Cost of sales
Gross profit
Research and development costs
Selling and marketing expenses
Manufacturing and distribution costs
General and administration costs
Other gains/(losses)(net)
Operating profit
Finance income
Finance costs
Profit/(loss) before income tax
Income tax benefit
Profit/(loss) for the period
Profit/(loss) for the period attributable to:
Owners of Telix Pharmaceuticals Limited
Items that will not be reclassified to profit or loss in subsequent periods:
Changes in the fair value of investments at fair value through other comprehensive income
Items to be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign operations
Total comprehensive income for the period
Total comprehensive income for the period attributable to:
Owners of Telix Pharmaceuticals Limited
Earnings per share [abstract]
Basic earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share)
Diluted earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share)